HIV treatment and
cure research

At Gilead, we seek to advance new treatment options that meet unmet needs for those living with HIV. Join a Gilead HIV trial to help further developments in treatment research.

Featured trials

STATUSStudy Complete

HIV treatment: GS-US-544-5905-05

A Phase 1b trial evaluating how medicines that stop HIV-1 from multiplying affect the course of infection in people living with HIV.

Gilead clinical trials fuel progress against HIV

Early on, HIV treatments were complex, burdensome, and could require more than 20 pills per day. Through advancements in research, treatment was able to be reduced to a couple of pills per day, a substantial improvement in HIV treatment. Our quest to improve HIV treatment options and expand our reach continues as we aim to pioneer and research long-acting treatments.

Find an HIV trial

Committed to ending the HIV epidemic

Although HIV is now considered a chronic, manageable disease, there is no cure. We are working to find a cure for HIV in our labs and with over 100 research partners. Gilead is also an integral part of the nationwide mission of Ending the HIV Epidemic (EHE), a federal effort designed to reduce new HIV infections by 90% by 2030.

Learn more

Voices in our communities

The power of many: HIV communities create lasting change

Beyond clinical trials: working together to address challenges in the HIV space

At Gilead we believe it takes a combination of both science and social efforts to make impactful progress against the HIV epidemic. By working with and supporting advocates and organizations across the country, we can make strides toward reaching this collective goal. Learn about Gilead's support of groups taking steps towards change, from My Brother's Keeper in Mississippi to Arianna's Center in South Florida.

View organizations

Explore our other HIV research areas

HIV prevention

For decades, Gilead has been at the forefront of HIV prevention, developing the first pre-exposure prophylaxis (PrEP) medication to help prevent HIV transmission. Gilead’s innovations continue today. Learn about Gilead’s HIV Prevention research efforts.

HIV in children

An estimated 1.7 million children under the age of 15 live with HIV. Gilead is deeply committed to the discovery and development of urgently needed, age-appropriate treatments for children living with HIV. Learn more about Gilead’s work in Pediatric HIV research.